WGS: financial statements from SEC — TradeAlmanac

WGS

GeneDx Holdings Corp.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Dec 31, 2025	Dec 31, 2024
Revenue	428m	305m
Cost of revenue	129m	111m
Gross profit	298m	194m
Research and development	72m	46m
Selling, general and administrative	151m	105m
Operating income	−13m	−23m
Pre-tax income	−21m	−53m
Income tax	−116,000	−343,000
Net income	−21m	−52m
Earnings per share	−0.73	−1.94
Earnings per share, diluted	−0.73	−1.94
Weighted average shares	29m	27m
Weighted average shares, diluted	29m	27m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	94m	105m	96m	74m	100m	85m	59m	57m
Short-term investments	77m	66m

Cash flow

Metric	Dec 31, 2025	Dec 31, 2024
Operating cash flow	33m	−28m
Depreciation and amortisation	25m	22m
Share-based compensation	32m	9m
Capital expenditure	19m	5m
Investing cash flow	−62m	−30m
Financing cash flow	48m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)